



Network Notification

Date: August 19, 2016
To: Ohio Medicaid Health Partners
From: CareSource®
Subject: Zika Virus Benefit Summary

CareSource, as a Medicaid Managed Care Organization (MCO), fully covers any testing and/or treatment related to the Zika Virus on behalf of our members. Please see details from Centers for Medicare and Medicaid Services (CMCS) below.

Additionally, we cover mosquito repellants without a Prior Authorization. The products below have been added to our formulary and are available to our members with a prescription:

GPI	PRODUCT ID	LABEL NAME	GPI NAME
90972540000900	46500001828	OFF FAMILYCR SPR 5%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500001835	OFF FAMILYCR SPR 7%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500001849	OFF DEEP WDS SPR 98.25%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500021845	OFF DEEP WDS SPR 25%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500051981	OFF FAMILYCR SPR 5%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500071787	OFF DEEP WDS SPR 25%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500071789	OFF FAMILYCR SPR 7%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500072616	OFF FAMILYCR SPR 7%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500072925	OFF DEEP WDS SPR 25%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	46500081846	OFF DEEP WDS SPR 25%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540000900	50716000718	MAXI DEET SPR 98.11%	*DIETHYLTOLUAMIDE (DEET) LIQUID***
90972540003200	51131067777	ULTRATHON AER INSECT	*DIETHYLTOLUAMIDE (DEET) AEROSOL***
90972540004100	51131067442	ULTRATHON LOT REPELLNT	*DIETHYLTOLUAMIDE (DEET) LOTION***
90972540009100	46500054996	OFF DEEP WDS MIS 25%	*DIETHYLTOLUAMIDE (DEET) SHEETS***
90972560000900	46500081881	OFF FAMILYCR SPR 5%	*PICARIDIN LIQUID***
90972560000900	50716000544	SAWYER REPEL SPR 20%	*PICARIDIN LIQUID***
90972560003200	44224006878	NATRAPEL 12H SPR 20%	*PICARIDIN AEROSOL***
90972590000900	68093000745	COLEMN INSEC LIQ SKINSMAR	*INSECT REPELLENT - LIQUID***
90972590000900	68093000746	COLEMN INSEC LIQ SKINSMAR	*INSECT REPELLENT - LIQUID***
90972590000900	68093007732	COLEMN BOTAN LIQ INSECT	*INSECT REPELLENT - LIQUID***
90972590003200	68093000747	COLEMN INSEC SPR SKINSMAR	*INSECT REPELLENT - AEROSOL***
90972595000900	00774031777	BULL FROG SPR MOSQUITO	*INSECT REPELLENT WITH SUNSCREEN - LIQUID***

Excerpts from CMCS Informational Bulletin dated 6/1/16:

Zika Virus Background

Outbreaks of Zika have been reported in Africa, the South Pacific and most recently in the Americas. The Zika virus is spread to people primarily through the bite of an infected *Aedes* (*Ae. aegypti* and *Ae. albopictus*) species mosquito. The Zika virus can also be sexually transmitted from a man to his partner(s) regardless of gender. The Centers for Disease Control and Prevention (CDC) urges that men at risk of or with recent Zika virus infection use condoms or abstain from sex to prevent transmission. The most common symptoms of Zika infection are fever, rash, joint pain, and conjunctivitis (red eyes). In past outbreaks, the illness has usually been mild with symptoms lasting for several days to a week after being bitten by an infected mosquito. People usually don't get sick enough to go to the hospital and they very rarely die of Zika infection. For this reason, many people might not realize they have been infected.

Zika virus infection during pregnancy can lead to serious health consequences. The CDC has stated that Zika virus can be passed from a pregnant woman to her fetus, and infection during pregnancy has been linked to a serious birth defect of the brain called microcephaly, which involves incomplete brain development, and other severe brain defects. Other problems have been detected in fetuses and infants infected with Zika virus, such as defects of the eye, hearing deficits, and impaired growth. A mother infected with the Zika virus near the time of delivery can pass on the virus to her newborn around the time of birth.

Zika has also been linked to Guillain-Barré syndrome (GBS), a rare disorder that can cause muscle weakness and paralysis for a few weeks to several months. Most people fully recover from GBS, but some have permanent damage.

The CDC is continuing to review medical information related to the Zika virus, and recently issued new guidance and information to prevent Zika virus transmission and its adverse health effects. Guidance includes updated interim guidance for healthcare professionals for counseling patients about pregnancy planning and the timing of pregnancy after possible exposure to Zika virus and updated interim guidance for preventing sexual transmission with information about how long men and women should consider using condoms or not having sex after possible exposure to Zika. We recommend monitoring the CDC website (www.cdc.gov/zika/index.html) for updated information and guidance on the Zika virus.

Prevention

There is no vaccine available for Zika virus. The major means of prevention currently available are mosquito control, protection against mosquito bites, and contraception for women of childbearing age who do not wish to become pregnant.

Detecting Zika Infection and Associated Health Risks

Diagnostic services are instrumental in detecting a Zika virus infection as well as associated health risks, such as microcephaly. They include services such as CAT scans, MRIs, ultrasounds, blood tests, urine tests, and genetic testing. For example, if a pregnant woman has recently traveled to an area with active mosquito-borne transmission of the Zika virus, her primary care doctor may recommend a blood test. If positive, her doctor may order an ultrasound to assess the health and development of the fetus. If abnormalities are detected, further testing may be required, including CAT scans and MRIs to ensure the health of the mother and fetus.

States are required to cover all medically necessary diagnostic services related to the detection of a Zika virus infection, including diagnosis of microcephaly and other birth defects without limit to individuals under the age of 21 through the Early Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.

Treatment

Treatment of individuals with the Zika virus or those with conditions that may be a result of the Zika virus is supported by services available through the Medicaid program.